16th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome

Lupus ◽  
2020 ◽  
Vol 29 (12) ◽  
pp. 1594-1600
Author(s):  
Ricard Cervera ◽  
Ignasi Rodríguez-Pintó ◽  
Kim Legault ◽  
Doruk Erkan

The Task Force on Catastrophic Antiphospholipid Syndrome (CAPS) met again on occasion of the 16th International Congress on Antiphospholipid Antibodies (aPL) that was held in Manchester, England, in September 2019. Its aims were to assess the up-to-date knowledge on pathogenesis, clinical and laboratory features, diagnosis and classification, precipitating factors, and treatment of CAPS. This article summarizes the main aspects that were presented during the Task Force meeting at that Congress.

2014 ◽  
Vol 13 (7) ◽  
pp. 699-707 ◽  
Author(s):  
Ricard Cervera ◽  
Ignasi Rodríguez-Pintó ◽  
Serena Colafrancesco ◽  
Fabrizio Conti ◽  
Guido Valesini ◽  
...  

2014 ◽  
Vol 13 (6) ◽  
pp. 685-696 ◽  
Author(s):  
Doruk Erkan ◽  
Cassyanne L. Aguiar ◽  
Danieli Andrade ◽  
Hannah Cohen ◽  
Maria J. Cuadrado ◽  
...  

Lupus ◽  
2021 ◽  
pp. 096120332110203
Author(s):  
Savino Sciascia ◽  
Massimo Radin ◽  
Irene Cecchi ◽  
Roger A Levy ◽  
Doruk Erkan

The objectives of the 16th International Congress on Antiphospholipid Antibodies (aPL) Task Force on Clinical Manifestations of Antiphospholipid Syndrome (APS) were to critically analyze: a) the definition of “APS”; b) the current knowledge on non-traditional manifestations associated with aPL; and c) the risk stratification strategies in aPL-positive patients. The quality of evidence was assessed by the GRADE system. The task force concluded that: a) APS does not have a uniform definition given the heterogeneity of the clinical presentations and different aPL profiles; b) current literature supports the role for aPL testing in cases of thrombocytopenia and recurrent cardiac events but are limited by vast heterogeneity, providing an overall low-to-very low level of evidence; and c) risk stratification strategies in aPL-positive patients, such as aPL-Score and Global APS Score, can be useful in clinical practice. International multicenter studies are still highly needed to improve the quality of available evidence and consequently the strength of future recommendations.


2014 ◽  
Vol 13 (9) ◽  
pp. 917-930 ◽  
Author(s):  
Maria Laura Bertolaccini ◽  
Olga Amengual ◽  
Laura Andreoli ◽  
Tatsuya Atsumi ◽  
Cecilia B. Chighizola ◽  
...  

2014 ◽  
Vol 13 (8) ◽  
pp. 795-813 ◽  
Author(s):  
Guilherme R. de Jesus ◽  
Nancy Agmon-Levin ◽  
Carlos A. Andrade ◽  
Laura Andreoli ◽  
Cecilia B. Chighizola ◽  
...  

Lupus ◽  
2020 ◽  
Vol 29 (12) ◽  
pp. 1601-1615 ◽  
Author(s):  
Guilherme R de Jesús ◽  
Ashley E Benson ◽  
Cecilia B Chighizola ◽  
Savino Sciascia ◽  
David W Branch

Obstetric antiphospholipid syndrome (APS) remains a clinical challenge for practitioners, with several controversial points that have not been answered so far. This Obstetric APS Task Force met on the 16th International Congress on Antiphospholipid Antibodies in Manchester, England, to discuss about treatment, diagnostic and clinical aspects of the disease. This report will address evidence-based medicine related to obstetric APS, including limitations on our current management, the relationship between antibodies against domain 1 of β2GPI and obstetric morbidity, hydroxychloroquine use in patients with obstetric APS and factors associated with thrombosis after obstetric APS. Finally, future directions for better understanding this complex condition are also reported by the Task Force coordinators.


Sign in / Sign up

Export Citation Format

Share Document